These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21729658)

  • 61. Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer.
    McCormack P; Sapunar F
    Clin Breast Cancer; 2008 Aug; 8(4):347-51. PubMed ID: 18757262
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost-effectiveness of fulvestrant 250 mg versus 500 mg in postmenopausal women with estrogen receptor-positive metastatic breast cancer and disease progression after antiestrogen therapy.
    Newman MJ; Jones LT; Kraft JM; Lee AR; Lech GM; Farrell NM; Phantumvanit V; Edwards RA
    J Oncol Pharm Pract; 2012 Dec; 18(4):394-401. PubMed ID: 22357638
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The oncology nurse's role in educating patients on endocrine therapy for metastatic breast cancer--focus on fulvestrant.
    Lynn J
    Cancer Nurs; 2002 Apr; 25 Suppl 2():12S-17S. PubMed ID: 12080536
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients.
    Poggio F; Lambertini M; Blondeaux E; Vaglica M; Levaggi A; Pronzato P; Del Mastro L
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1153-61. PubMed ID: 27545815
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Assessment of the clinical efficacy and safety of fulvestrant in heavily pretreated patients with hormone-receptor positive metastatic breast cancer-a single-institution experience].
    Hattori M; Horio A; Sawaki M; Kondo N; Fujita T; Ushio A; Gondo N; Idota A; Ichikawa M; Iwata H
    Gan To Kagaku Ryoho; 2013 Dec; 40(13):2535-8. PubMed ID: 24335365
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer.
    Robertson JF
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):209-12. PubMed ID: 11850227
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Current and future perspectives on fulvestrant.
    Gradishar WJ; Sahmoud T
    Clin Breast Cancer; 2005 Apr; 6 Suppl 1():S23-9. PubMed ID: 15865847
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials.
    Lin WZ; Xu QN; Wang HB; Li XY
    Breast Cancer; 2017 May; 24(3):345-352. PubMed ID: 28324247
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer.
    Robertson JF; Harrison MP
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):346-8. PubMed ID: 12879276
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Estrogen receptor downregulators: new antihormonal therapy for advanced breast cancer.
    Robertson JF
    Clin Ther; 2002; 24 Suppl A():A17-30. PubMed ID: 11911506
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review.
    Flemming J; Madarnas Y; Franek JA
    Breast Cancer Res Treat; 2009 May; 115(2):255-68. PubMed ID: 18683044
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Fulvestrant].
    Roth S; Schaad S; Hardel V; Jaehde U
    Dtsch Med Wochenschr; 2006 Dec; 131(48):2718-21. PubMed ID: 17123238
    [No Abstract]   [Full Text] [Related]  

  • 73. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.
    Di Leo A; Jerusalem G; Petruzelka L; Torres R; Bondarenko IN; Khasanov R; Verhoeven D; Pedrini JL; Smirnova I; Lichinitser MR; Pendergrass K; Malorni L; Garnett S; Rukazenkov Y; Martin M
    J Natl Cancer Inst; 2014 Jan; 106(1):djt337. PubMed ID: 24317176
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Finding the right dose of fulvestrant in breast cancer.
    Estévez L; Alvarez I; Tusquets I; Seguí MA; Muñoz M; Fernández Y; Lluch A
    Cancer Treat Rev; 2013 Apr; 39(2):136-41. PubMed ID: 22795960
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers.
    Addo S; Yates RA; Laight A
    Br J Cancer; 2002 Dec; 87(12):1354-9. PubMed ID: 12454761
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Fulvestrant for the treatment of endometrial cancer.
    Battista MJ; Schmidt M
    Expert Opin Investig Drugs; 2016; 25(4):475-83. PubMed ID: 26882357
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical experience with fulvestrant ('Faslodex'): a nurse's perspective.
    Owers R
    Eur J Oncol Nurs; 2004; 8 Suppl 2():S89-94. PubMed ID: 15590320
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Faslodex (ICI 182780). an oestrogen receptor downregulator.
    Howell A
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S87-8. PubMed ID: 11056334
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer.
    Cameron DA; Camidge DR; Oyee J; Hirsch M
    Br J Cancer; 2008 Dec; 99(12):1984-90. PubMed ID: 19018261
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Fulvestrant (faslodex) for advanced breast cancer.
    Med Lett Drugs Ther; 2002 Jul; 44(1135):65-6. PubMed ID: 12138378
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.